Recruiting at 3 sites Phase 1, Phase 2 Childhood-onset Systemic Lupus Erythematous

Childhood-onset Systemic Lupus Erythematous study: Descartes-08

Official title Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

ClinicalTrials.gov ID: NCT07089121

What this study is testing

What is Descartes-08?

an investigational drug being studied as a potential treatment for childhood-onset systemic lupus erythematosus and other pediatric autoimmune diseases

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The study aims to see if Descartes‑08 is safe, tolerable, and works for these conditions.
Who it's for
Children, adolescents, and young adults diagnosed with childhood‑onset lupus, ANCA‑associated vasculitis, juvenile myasthenia gravis, or juvenile dermatomyositis.
What's involved
Participants will receive the investigational drug Descartes‑08 and undergo regular medical visits and tests to monitor safety and response.
  • Phase 2: a mid-size study of how well it works

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 12 and older

You may be able to join if

  • At least age 12
  • definitive diagnosis of childhood-onset systemic lupus erythematous, juvenile Myasthenie gravis, juvenile dermatomyositis and AAV
  • Signs and symptoms of moderate disease
  • History of systemic treatment
  • Parent/Guardian/Patient must be able to give written informed consent

You likely can't join if

  • Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient;
  • Abnormal PT/INR or PTT increased \> 1.5-fold or patient is on anticoagulation therapy (except in cases of elevated PTT with documented lupus...
  • ANC \< 1000 cells/microliter ;
  • Hemoglobin \< 8.0 g/dL ;
  • Platelets \< 50,000/mm3 (NOTE: platelet transfusions are permissible);
  • ALT and/or AST with GGT ≥ 3× upper limit of normal
See the full eligibility criteria
Who can join
  • At least age 12
  • definitive diagnosis of childhood-onset systemic lupus erythematous, juvenile Myasthenie gravis, juvenile dermatomyositis and AAV
  • Signs and symptoms of moderate disease
  • History of systemic treatment
  • Parent/Guardian/Patient must be able to give written informed consent
What rules you out
  • Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient;
  • Abnormal PT/INR or PTT increased \> 1.5-fold or patient is on anticoagulation therapy (except in cases of elevated PTT with documented lupus anticoagulant
  • ANC \< 1000 cells/microliter ;
  • Hemoglobin \< 8.0 g/dL ;
  • Platelets \< 50,000/mm3 (NOTE: platelet transfusions are permissible);
  • ALT and/or AST with GGT ≥ 3× upper limit of normal
  • Creatine Clearance less than 30mL/min /1.73 m2;
  • History of primary immunodeficiency, organ, or allogeneic bone marrow transplant;
  • Patients must be seronegative for hepatitis B surface antigen;
  • Patients must be seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patients must be tested for the presence of viremia by RT-PCR and must be HCV RNA negative;
  • History of positive HIV or positive HIV at screening;
  • Active tuberculosis or positive QuantiFERON test at screening;
  • Any other laboratory abnormality that, in the opinion of the investigator, may jeopardize the subject's ability to participate in the study; 23.

The study team makes the final eligibility decision.

Where it is enrolling

  • Washington D.C., District of Columbia, United States
  • St Louis, Missouri, United States
  • Cincinnati, Ohio, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 12 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Washington D.C., District of Columbia, United States; St Louis, Missouri, United States; Cincinnati, Ohio, United States. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.